| Overview |
| bs-4592R-Cy5.5 |
| CDKN2A/p16INK4a Polyclonal Antibody, Cy5.5 Conjugated |
| FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Targets p16INK4a |
| Human |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CDKN2A |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 1029 |
| P42771 |
| Nucleus |
| Cyclin-dependent kinase inhibitor 2A; Cyclin-dependent kinase 4 inhibitor A; CDK4I; Multiple tumor suppressor 1; MTS-1; p16-INK4a; p16-INK4; p16INK4A; p12; CDKN2; MTS1. |
| Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein. |
| Application Dilution |
| FCM |
1:20-100 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz